药品注册申请号:125377
申请类型:BLA (生物制品许可申请)
申请人:BRISTOL MYERS SQUIBB
申请人全名:--
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 YERVOY IPILIMUMAB INJECTABLE; INJECTION 3MG No No None 2011/03/25 -- Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
审批日期提交号审批结论提交分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2011/03/25 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY ;Orphan
>>>补充申请<<<
审批日期提交号审批结论补充类别或审批类型审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2025/05/23 SUPPL-136(补充) Approval Efficacy-New Indication PRIORITY ;Orphan
2025/04/11 SUPPL-133(补充) Approval Efficacy-Accelerated Approval STANDARD ;Orphan
2025/04/08 SUPPL-135(补充) Approval Efficacy-Accelerated Approval PRIORITY ;Orphan
2025/01/28 SUPPL-132(补充) Approval Efficacy-New Dosing Regimen STANDARD ;Orphan
2023/02/15 SUPPL-129(补充) Approval Efficacy-New Patient Population PRIORITY ;Orphan
2022/11/23 SUPPL-130(补充) Approval Labeling-Package Insert,Labeling-Medication Guide STANDARD ;Orphan
2022/05/27 SUPPL-122(补充) Approval Efficacy-New Indication STANDARD
2022/05/11 SUPPL-124(补充) Approval Efficacy-New Dosing Regimen STANDARD
2022/02/25 SUPPL-127(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2022/02/25 SUPPL-126(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2021/05/25 SUPPL-121(补充) Approval Efficacy-Labeling Change With Clinical Data STANDARD
2020/11/13 SUPPL-119(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2020/10/02 SUPPL-115(补充) Approval Efficacy-New Indication PRIORITY
2020/09/18 SUPPL-112(补充) Approval Efficacy-Labeling Change With Clinical Data STANDARD
2020/08/13 SUPPL-111(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2020/06/29 SUPPL-106(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2020/05/26 SUPPL-110(补充) Approval Efficacy-New Indication PRIORITY
2020/05/15 SUPPL-109(补充) Approval Efficacy-New Indication PRIORITY
2020/03/10 SUPPL-108(补充) Approval Efficacy-New Indication PRIORITY
2019/09/20 SUPPL-104(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2019/05/08 SUPPL-102(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2018/07/10 SUPPL-96(补充) Approval Efficacy-New Indication PRIORITY
2018/04/16 SUPPL-94(补充) Approval Efficacy-New Indication PRIORITY
2018/02/08 SUPPL-93(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2017/12/13 SUPPL-91(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2017/10/20 SUPPL-86(补充) Approval Efficacy-Labeling Change With Clinical Data STANDARD ;Orphan
2017/07/21 SUPPL-87(补充) Approval Efficacy-New Indication STANDARD ;Orphan
2017/03/03 SUPPL-84(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2015/10/28 SUPPL-73(补充) Approval Efficacy-New Indication STANDARD ;Orphan
2015/08/17 SUPPL-74(补充) Approval Labeling-Package Insert,Labeling-Medication Guide STANDARD ;Orphan
2015/03/19 SUPPL-72(补充) Approval Labeling-Package Insert STANDARD ;Orphan
2015/03/16 SUPPL-71(补充) Approval REMS-Modified N/A
2013/12/05 SUPPL-55(补充) Approval Labeling STANDARD
2013/05/22 SUPPL-44(补充) Approval Labeling STANDARD
2012/10/26 SUPPL-33(补充) Approval Labeling STANDARD
2012/02/16 SUPPL-16(补充) Approval Labeling STANDARD
2011/07/28 SUPPL-8(补充) Approval Labeling STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
本品无治疗等效药品
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2025 DrugFuture->U.S. FDA Drugs Database